DBPs

项目摘要 推动生物医学项目组合 为了推动我们分子显微镜产品线的发展，我们选择了Driving Biomedical Projects （二）作为应用和测试国家清洁生产技术的第一阶段的消毒副产品。每个DBP包含一个或多个 关键的具体技术障碍，已被该领域普遍承认，必须 通过我们管道中不同阶段的技术开发和优化来克服。总的来说， 选择这些消毒副产物是为了测试该管道中的所有技术：帮助开发样品制备方法 以及隔离完整的本机程序集的方法;确保开发和改进 确定分离复合物的组成、化学计量、形态和连接性;并计划 对大型高分子机器静态结构建模方法的发展也提出了挑战 这些机器在长时间尺度上的动态过程。我们也挑选了这些消毒副产品， 代表了不同的生物学问题，“细胞信息途径”的关键部分， 细胞，导致染色质中DNA的重组和激活，以转录成RNA， 加工、包装并输出到细胞质中，在细胞质中翻译成蛋白质，从而产生 新的装配结构和细胞器因此，这些DBP是我们的 在解决关键技术障碍和解决研究中的关键生物医学挑战方面， 我们服务的社区在这样做的过程中，我们将产生新的工具，技术和试剂的interactomic研究， 训练DBP成员在分子显微镜管道的方法，开始这些传播 通过这种培训和在会议和论文中的介绍，接触更广泛的研究人员群体， 并帮助稳定这些方法，以在社区中可持续地存在。我们也期待 在DBPs中应用我们的TR&D技术，以产生新的挑战，反馈以帮助推动新的 我们正在进行的研发开发和成熟的方面。

PROJECT SUMMARY Driving Biomedical Projects Portfolio To drive the development of our molecular microscope pipeline, we have selected Driving Biomedical Projects (DBPs) that serve as the first stage in applying and testing NCDIR technologies. Each DBP contains one or more key specific technological roadblocks that have been generally acknowledged by the field and that must be overcome by the development and optimization of technologies at different stages in our pipeline. Collectively, these DBPs are selected to test all the technology in this pipeline: helping develop sample preparation methods and ways to isolate intact native assemblies; ensuring the development and refinement of methods that determine the composition, stoichiometry, morphology and connectivity of isolated complexes; and projects that challenge the development of methods for modeling static structures of large macromolecular machines as well as dynamic processes involving these machines on long time scales. We have also selected these DBPs to represent different biological problems, key pieces of the “cellular information pathway” that starts with signalling to a cell, leading to reorganization and activation of DNA in chromatin for transcription into RNA, which is processed, packaged, and exported into the cytoplasm where its translation into protein leads to the generation of new assemblies, structures, and organelles. These DBPs are therefore a key metric for the efficacy of our technologies in both solving key technical roadblocks and addressing key biomedical challenges in the research community we serve. In doing so, we will generate new tools, techniques, and reagents for interactomic studies, train DBP members in the molecular microscope pipeline approaches, begin the dissemination of these approaches to a wider group of researchers both through this training and presentation in meetings and papers, and aid the stabilization of these approaches for a sustainable presence in the community. We also expect application of our TR&D technology in the DBPs to generate new challenges, feeding back to help drive new aspects of our ongoing TR&D development and maturation.